FREE ELECTRONIC LIBRARY - Books, dissertations, abstract

Pages:     | 1 |   ...   | 6 | 7 || 9 | 10 |   ...   | 34 |

«2013 Annual Report breakthrough technologies and services focused on Dear Fellow Shareholders, addressing specific customer and market needs. Several ...»

-- [ Page 8 ] --

Robert F. Friel, 58. Mr. Friel was named our Chief Executive Officer in February 2008. Mr. Friel joined us in February 1999 as our Senior Vice President and Chief Financial Officer. In 2004, he was named Executive Vice President and Chief Financial Officer with responsibility for business development and information technology, in addition to his oversight of the finance function. In January 2006, he was named our Vice Chairman, President of Life and Analytical Sciences and elected to our Board. In July 2007, he was named President and Chief Operating Officer, effective August 1, 2007. From 1980 to 1999, he held several senior management positions with AlliedSignal, Inc., now Honeywell International. He holds a Bachelor of Arts degree in economics from Lafayette College and a Master of Science degree in taxation from Fairleigh Dickinson University. Mr. Friel is currently a director of CareFusion Corporation and Xylem Inc., and has served as a director of Fairchild Semiconductor Corp. and Millennium Pharmaceuticals, Inc. He also previously served on the national board of trustees for the March of Dimes Foundation.

Frank A. Wilson, 55. Mr. Wilson joined us in May 2009 and is our Senior Vice President and Chief Financial Officer. Prior to joining us in May 2009, Mr. Wilson held key financial and business management roles over 12 years at the Danaher Corporation, including Corporate Vice President of Investor Relations; Group Vice President of Business Development; Group Vice President of Finance for Danaher Motion Group; President of Gems Sensors; and Group Vice President of Finance for the Industrial Controls Group. Before joining Danaher, Mr. Wilson worked for several years at AlliedSignal Inc., now Honeywell International, where he last served as Vice President of Finance and Chief Financial Officer for Commercial Aviations Systems. Prior to joining AlliedSignal Inc., he worked at PepsiCo Inc. in financial and controllership positions of increasing responsibility, E.F. Hutton and Company, and KPMG Peat Marwick. Mr. Wilson received a Bachelor’s degree in business administration from Baylor University and is also a Certified Public Accountant.

Joel S. Goldberg, 45. Mr. Goldberg joined us in July 2008 as our Senior Vice President, General Counsel and Secretary. Prior to joining us in July 2008, Mr. Goldberg served as Vice President, Chief Compliance Officer and Secretary for Millennium Pharmaceuticals, Inc. During his seven years with Millennium, he focused in the areas of mergers and acquisitions, strategic alliances, investment and financing transactions, securities and healthcare related compliance, and employment law. Before joining Millennium, Mr. Goldberg was an associate at the law firm of Edwards & Angell, LLP, focusing on emerging companies, venture capital, securities and merger-related work. Mr. Goldberg graduated from the Northeastern University School of Law and also holds a Masters in Business Administration from Northeastern University. He completed his undergraduate degree at the University of Wisconsin-Madison.

Daniel R. Marshak, 56. Dr. Marshak was appointed our Senior Vice President in April 2008, having joined us as our Chief Scientific Officer in May 2006. In addition to these responsibilities, in May 2010, Dr. Marshak was appointed President of our Emerging Diagnostics business. Dr. Marshak previously held the position of President, Greater China for us. Prior to joining us, Dr. Marshak was with Cambrex Corporation since 2000, most recently as Vice President and Chief Technology Officer for Biotechnology. Dr. Marshak also previously held the positions of Senior Vice President and Chief Scientific Officer for Osiris Therapeutics, Inc. and Senior Staff Investigator, Cold Spring Harbor Laboratory. Dr. Marshak received his Bachelor of Arts degree in biochemistry and molecular biology from Harvard University, and his doctorate in biochemistry and cell biology from The Rockefeller University. Dr. Marshak performed postdoctoral research in pharmacology at Vanderbilt University and the National Institute of Health. Dr. Marshak is the author of more than 100 scientific publications and an inventor on six United States patents.

John R. Letcher, 52. Mr. Letcher was appointed our Senior Vice President of Human Resources, in February

2010. He joined us in 1999 as our Vice President of Human Resources for the Optoelectronics business unit and, in 2003, was named Vice President of Human Resources for the Life and Analytical Sciences business unit. In 2008, Mr. Letcher was named our Vice President Human Resources for all of our business units. Previously, he served as Director of Human Resources of ABB Americas, Inc., the U.S. subsidiary of an international engineering company. Prior to that, Mr. Letcher held the positions of Business Controller in ABB Americas, Inc.’s US Power Generation Gas Turbine Power business; Vice President of Finance for General Ship Corporation and Senior Auditor for Arthur Andersen. Mr. Letcher holds a Bachelor of Science degree in accounting and information technology from Boston College.

James Corbett, 51. Mr. Corbett was appointed our Senior Vice President of Diagnostics / Life Sciences and Technology in May 2013. He joined us in November 2007 as President for the ViaCord business unit through the acquisition of ViaCell, Inc. Mr. Corbett also has served as Vice President and General Manager of the Americas for the Diagnostics business unit and has been President of our Diagnostics business unit since May 2010. Prior to joining us, he held positions in Abbott Laboratories, BioChem Immunosystems, CADx Systems, and iCad.

Mr. Corbett holds a Bachelor of Science degree in business from the University of Massachusetts.

Jon DiVincenzo, 48. Mr. DiVincenzo was appointed Senior Vice President and President of our Environmental Health business in November 2013. Prior to joining us, Mr. DiVincenzo served as the President and Chief Executive Officer of Enzymatics, a provider of molecular biology reagents, in 2013. From 1994 through 2012, Mr. DiVincenzo worked at Millipore Corporation, where he last served as President of the bioscience division and also led the lab water business. Mr. DiVincenzo holds a Bachelor of Science degree in mechanical engineering from Northeastern University where he currently serves on the College of Engineering’s Advisory Council. He is also a member of the Corporate Executive Board for Innovation and former member of the Board of Directors of the Analytical Life Sciences and Diagnostics Association.

Maurice (Dusty) H. Tenney, III, 50. Mr. Tenney was appointed our Senior Vice President and President, Global Operations and Customer Logistics in November 2013. He joined us in 2001 as Vice President of Global Operations for the Analytical Instruments business unit and, in 2004, was named President of our Laboratory Services business unit. In 2009 he was appointed President of our Environmental Health business unit (formerly known as our Analytical Sciences and Laboratory Services business unit). Prior to joining us, he held positions with Honeywell, Lockheed Martin and GE Aerospace. Mr. Tenney holds a Bachelor of Science degree in mechanical engineering from the University of Maryland and a Master of Science degree in mechanical engineering from the University of Vermont.

Andrew Okun, 44. Mr. Okun was appointed our Vice President and Chief Accounting Officer in April 2011.

He joined us in 2001 as part of the controllership organization for the Optoelectronics business unit and over the next eight years Mr. Okun assumed positions of increasing responsibility in the areas of controllership and financial planning and analysis, including serving as Controller for the Optoelectronics business unit. In 2009, Mr. Okun was named our Vice President and Corporate Controller. Prior to joining us, he held positions with Honeywell, ultimately becoming the Site Controller for its Commercial Avionics business, and the position of Senior Tax Associate for Coopers & Lybrand. Mr. Okun holds a Bachelor of Arts degree in economics from the University of California at Santa Barbara, a Masters in Business Administration from the University of Virginia, and is a Certified Public Accountant.


Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Price of Common Stock Our common stock is listed and traded on the New York Stock Exchange. The following table sets forth the high and low per share closing sale prices for our common stock on that exchange for each quarter in fiscal years 2013 and 2012.

–  –  –

As of February 20, 2014, we had approximately 4,750 holders of record of our common stock.

Stock Repurchase Program The following table provides information with respect to the shares of common stock repurchased by us for the periods indicated.

–  –  –

(1) On October 24, 2012, our Board authorized us to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 24, 2014 unless terminated earlier by our Board, and may be suspended or discontinued at any time.

During the fourth quarter of fiscal year 2013, we did not repurchase any shares of common stock in the open market under the Repurchase Program. As of December 29, 2013, approximately 2.4 million shares authorized by our Board under the Repurchase Program remained available for repurchase. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.

(2) Our Board has authorized us to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to our equity incentive plans. During the fourth quarter of fiscal year 2013, we repurchased 5,529 shares of common stock for this purpose. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.

Dividends During fiscal years 2013 and 2012, we declared regular quarterly cash dividends on our common stock. The table below sets forth the cash dividends per share that we declared on our common stock during each of those fiscal years, by quarter.

2013 Fiscal Quarters 2013 Total First Second Third Fourth

–  –  –

While it is our current intention to pay regular quarterly cash dividends, any decision to pay future cash dividends will be made by our Board and will depend on our earnings, financial condition and other factors. Our Board may reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. For further information related to our stockholders’ equity, see Note 19 to our consolidated financial statements included in this annual report on Form 10-K.

Stock Performance Graph Set forth below is a line graph comparing the cumulative total shareholder return on our common stock against the cumulative total return of the S&P Composite-500 Index and a Peer Group Index for the five fiscal years from December 28, 2008 to December 29, 2013. Our Peer Group Index consists of Affymetrix, Inc., Agilent Technologies Inc., Life Technologies Corporation, Thermo Fisher Scientific Inc., and Waters Corporation.

–  –  –

Pages:     | 1 |   ...   | 6 | 7 || 9 | 10 |   ...   | 34 |

Similar works:

«2 Sequence Alignment Reviews Sequence Alignment in HIV Computational Analysis Ana Abecasis1,2,*, Anne-Mieke Vandamme1,3, and Philippe Lemey1,4 Laboratory for Clinical and Epidemiological Virology, REGA Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium Laboratory of Virology, Hospital de Egas Moniz, Centro Hospital de Lisboa Ocidental, Lisboa, Portugal Center for Bioinformatics, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisboa, Portugal Department of Zoology,...»

«DEPARTMENT OF JUSTICE GUIDANCE CONCERNING ENVIRONMENTAL JUSTICE Authority: Executive Order No. 12898 (59 Fed. Reg. 7629 (Feb. 16, 1994)} Section I Background Contents: Section II Executive Order No. 12898 Department Goals Section III Section IV Implementation Judicial Review and Enforcement Section V I. BACKGROUND As a result of the public’s concern regarding the quality of the physical environment, the Federal and state governments have enacted legislation to safeguard the environment and...»

«Hans Neuenschwander Christoph Cina Herausgeber Handbuch Palliativmedizin 3., vollständig überarbeitete Auflage Neuenschwander/Cina (Hrsg.) Verlag Hans Huber Handbuch Palliativmedizin Programmbereich Medizin © 2015 by Verlag Hans Huber, Hogrefe AG, Bern Dieses Dokument ist nur für den persönlichen Gebrauch bestimmt und darf in keiner Form vervielfältigt und an Dritte weitergegeben werden. Aus: Hans Neuenschwander, Christoph Cina; Handbuch Palliativmedizin. 3., vollständig überarbeitete...»

«HUD-VASH Qs & As These Qs & As serve as a supplement to the HUD-VASH Operating Requirements published in the Federal Register on May 6 and 19, 2008. A. Eligibility and Admission 1. If a veteran is interested in participating in the HUD-VASH program, whom should he or she contact? The case managers at the local Veterans Affairs Medical Centers (VAMC) are responsible for referring eligible homeless veterans to the PHAs. Therefore, any interested homeless veteran should contact their local VAMC...»

«Comprehensive Services and School Readiness Protocol Integrated Services Team-Management Guide Family Child Care The participants in the Integrated Service Team -Management interview include all managers/coordinators responsible for providing program oversight in Education, Family Services, Health, Nutrition, and Mental Health. Key Performance Area #1 Identifying Child and Family Strengths and Needs Describe how you: • Identify needs and determine if family needs are met or family progress is...»

«HIV-spezifische DNA-Impfstoffe mit verbessertem Sicherheitsund Wirksamkeitsprofil: Grundlage innovativer Vakzinestrategien DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR.RER.NAT.) DER NATURWISSENSCHAFTLICHEN FAKULTÄT III -BIOLOGIE UND VORKLINISCHE MEDIZINDER UNIVERSITÄT REGENSBURG vorgelegt von Kurt Bieler aus Weiden Mai 2002 Die vorliegende Dissertation wurde zwischen März 1998 und Mai 2002 am Institut für Medizinische Mikrobiologie und Hygiene an der Universität...»

«D I V I S I ON O F C H I L D C A R E A N D E A R L Y C H I L D H O OD E D U C A T I ON H E A L T H A N D N U T R I T I ON U N I T P O B O X 1 4 3 7, S L OT S 1 5 5 501-320-8982 · FAX: 501-682-2334 · TDD: 501-682-1550 MEMORANDUM INTERNAL CONTROL REQUIREMENTS FOR NON-PROFITS TO: NON-PROFIT INSTITUTIONS FROM: HEALTH AND NUTRITION UNIT SUBJECT: INTERNAL CONTROLS DATE: FEBRUARY 24, 2016 SUMMARY This Memorandum provides information on the written internal control requirements for non-profit...»

«Aus der Anästhesiologischen Klinik der Friedrich-Alexander-Universität Erlangen-Nürnberg Direktor: Prof. Dr. med. Dr. h. c. J. Schüttler Vergleich des Verlaufs der neuromuskulären Blockade nach Applikation von Mivacurium bei Schulkindern unterschiedlicher Altersgruppen im Rahmen einer Total intravenösen Anästhesie Inaugural-Dissertation zur Erlangung der Doktorwürde der Medizinischen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg vorgelegt von Sebastian Krinner aus...»

«Aus dem Institut für Mikrobiologie und Hygiene, Universitätsklinikum Charité, Humboldt-Universität zu Berlin DISSERTATION Charakterisierung LPS-inhibierender Effekte von Lipoproteinen und Lipopolysaccharid Bindendem Protein (LBP) in murinem Serum Zur Erlangung der medizinischen Doktorwürde Vorgelegt der Medizinischen Fakultät der Humboldt-Universität zu Berlin vorgelegt von Jan Holger Knierim aus Rendsburg Dekan: Prof. Dr. Dr. h.c. Roland Felix Gutachter: 1. Priv.-Doz. Dr. med. R.R....»

«This is an author-produced electronic version of an article accepted for publication in the British Journal of Psychiatry. The definitive publisherauthenticated version is available online at http://bjp.rcpsych.org. The CIDI-Core Substance Abuse and Dependence Questions: Cross-cultural and Nosological Issues L. B. COTTLER, L. N. ROBINS, B. F. GRANT, J. BLAINE, L. H. TOWLE, H.-U.WITTCHEN, N. SARTORIUS and PARTICIPANTS IN THE WHO/ADAMHA FIELD TRIAL The CIDI is a fully standardised, structured...»

<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.